Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02663999 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

A Phase 1 study, sponsored by Acorda Therapeutics.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target

NCT02663999 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02663999, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

This is a single-center, two-period, randomized, open-label, crossover pharmacokinetic (PK) study in healthy adult volunteers to evaluate dose proportionality of diazepam nasal spray using two dose levels

Interventions

  • DRUG diazepam nasal spray

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2016-01
Est. Completion 2016-06
Phase Phase 1

Sponsor

Acorda Therapeutics

36 total trials

What the Registry Record Tells You About NCT02663999

The ClinicalTrials.gov registry entry for NCT02663999 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which diazepam nasal spray is the first listed.

NCT02663999 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02663999 about?

NCT02663999 is a clinical study titled "A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers". This is a single-center, two-period, randomized, open-label, crossover pharmacokinetic (PK) study in healthy adult volunteers to evaluate dose proportionality of diazepam nasal spray using two dose levels

What is the current status of trial NCT02663999?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-01. Estimated completion is 2016-06.

What interventions are being tested in trial NCT02663999?

The interventions under investigation include: diazepam nasal spray (DRUG).

Who is sponsoring clinical trial NCT02663999?

This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.